Theresa Wingrove - 15 Nov 2023 Form 4 Insider Report for ImmunoGen, Inc.

Role
SVP OF REGULATORY AFFAIRS
Signature
/s/ Renee Lentini, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Nov 2023
Net transactions value
-$1,883,992
Form type
4
Filing time
17 Nov 2023, 19:53:59 UTC
Previous filing
08 Nov 2023
Next filing
01 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGN Common Stock Options Exercise $758,599 +166,725 +5931% $4.55 169,536 15 Nov 2023 Direct F1
transaction IMGN Common Stock Sale $2,642,591 -166,725 -98% $15.85 2,811 15 Nov 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGN Stock Option (right to buy) Options Exercise $0 -166,725 -80% $0.000000 41,681 15 Nov 2023 Common Stock 166,725 $4.55 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on June 13, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.58 to $16.03, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within these ranges.
F3 On 2/7/2020, the reporting person was granted an option to purchase 333,450 shares of common stock. The option vests in installments upon the satisfaction of certain performance criteria. As of the transaction date, 75% of the awarded options are vested.